FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo Rifamycin SV MMXÂ for Travelers Diarrhea

Upon FDA Approval Aries Pharmaceuticals Inc. to Lead U.S. Commercial Efforts Cosmo Pharmaceuticals N.V. SIX COPN today announced that the U.S. Food and Drug Administration FDA has granted both Qualified Infectious Dis...